Last reviewed · How we verify

Topical cyclopentolate and phenylephrine

Dar El Oyoun Hospital · FDA-approved active Small molecule ✓ Verified May 2026

Topical cyclopentolate and phenylephrine is a Anticholinergic agent + alpha-1 adrenergic agonist Small molecule drug developed by Dar El Oyoun Hospital. It is currently FDA-approved for Mydriasis and cycloplegia for ophthalmic examination and refraction, Mydriasis for ophthalmic diagnostic procedures. Also known as: Cyclophrine eye drops.

Cyclopentolate blocks muscarinic acetylcholine receptors to cause mydriasis and cycloplegia, while phenylephrine stimulates alpha-1 adrenergic receptors to enhance mydriasis.

Topical cyclopentolate and phenylephrine are small molecule medications used to treat conditions such as cataract and corneal endothelial cell loss, and to induce mydriasis. They are administered topically and have been studied in clinical trials for their efficacy and safety in these applications.

At a glance

Generic nameTopical cyclopentolate and phenylephrine
Also known asCyclophrine eye drops
SponsorDar El Oyoun Hospital
Drug classAnticholinergic agent + alpha-1 adrenergic agonist
TargetMuscarinic acetylcholine receptor (cyclopentolate); alpha-1 adrenergic receptor (phenylephrine)
ModalitySmall molecule
Therapeutic areaOphthalmology
PhaseFDA-approved

Mechanism of action

Cyclopentolate is an anticholinergic agent that paralyzes the ciliary muscle and dilates the pupil by blocking parasympathetic signaling. Phenylephrine is an alpha-1 adrenergic agonist that further dilates the pupil through sympathomimetic action. Together, this combination produces rapid and pronounced mydriasis and cycloplegia for diagnostic and therapeutic ophthalmic procedures.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Topical cyclopentolate and phenylephrine

What is Topical cyclopentolate and phenylephrine?

Topical cyclopentolate and phenylephrine is a Anticholinergic agent + alpha-1 adrenergic agonist drug developed by Dar El Oyoun Hospital, indicated for Mydriasis and cycloplegia for ophthalmic examination and refraction, Mydriasis for ophthalmic diagnostic procedures.

How does Topical cyclopentolate and phenylephrine work?

Cyclopentolate blocks muscarinic acetylcholine receptors to cause mydriasis and cycloplegia, while phenylephrine stimulates alpha-1 adrenergic receptors to enhance mydriasis.

What is Topical cyclopentolate and phenylephrine used for?

Topical cyclopentolate and phenylephrine is indicated for Mydriasis and cycloplegia for ophthalmic examination and refraction, Mydriasis for ophthalmic diagnostic procedures.

Who makes Topical cyclopentolate and phenylephrine?

Topical cyclopentolate and phenylephrine is developed and marketed by Dar El Oyoun Hospital (see full Dar El Oyoun Hospital pipeline at /company/dar-el-oyoun-hospital).

Is Topical cyclopentolate and phenylephrine also known as anything else?

Topical cyclopentolate and phenylephrine is also known as Cyclophrine eye drops.

What drug class is Topical cyclopentolate and phenylephrine in?

Topical cyclopentolate and phenylephrine belongs to the Anticholinergic agent + alpha-1 adrenergic agonist class. See all Anticholinergic agent + alpha-1 adrenergic agonist drugs at /class/anticholinergic-agent-alpha-1-adrenergic-agonist.

What development phase is Topical cyclopentolate and phenylephrine in?

Topical cyclopentolate and phenylephrine is FDA-approved (marketed).

What are the side effects of Topical cyclopentolate and phenylephrine?

Common side effects of Topical cyclopentolate and phenylephrine include Transient stinging or irritation, Blurred vision, Photophobia, Increased intraocular pressure, Systemic anticholinergic effects (rare with topical use).

What does Topical cyclopentolate and phenylephrine target?

Topical cyclopentolate and phenylephrine targets Muscarinic acetylcholine receptor (cyclopentolate); alpha-1 adrenergic receptor (phenylephrine) and is a Anticholinergic agent + alpha-1 adrenergic agonist.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing